» Articles » PMID: 33921556

Alternative Targets to Fight Alzheimer's Disease: Focus on Astrocytes

Overview
Journal Biomolecules
Publisher MDPI
Date 2021 Apr 30
PMID 33921556
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

The available treatments for patients affected by Alzheimer's disease (AD) are not curative. Numerous clinical trials have failed during the past decades. Therefore, scientists need to explore new avenues to tackle this disease. In the present review, we briefly summarize the pathological mechanisms of AD known so far, based on which different therapeutic tools have been designed. Then, we focus on a specific approach that is targeting astrocytes. Indeed, these non-neuronal brain cells respond to any insult, injury, or disease of the brain, including AD. The study of astrocytes is complicated by the fact that they exert a plethora of homeostatic functions, and their disease-induced changes could be context-, time-, and disease specific. However, this complex but fervent area of research has produced a large amount of data targeting different astrocytic functions using pharmacological approaches. Here, we review the most recent literature findings that have been published in the last five years to stimulate new hypotheses and ideas to work on, highlighting the peculiar ability of palmitoylethanolamide to modulate astrocytes according to their morpho-functional state, which ultimately suggests a possible potential disease-modifying therapeutic approach for AD.

Citing Articles

The identification of a Distinct Astrocyte Subtype that Diminishes in Alzheimer's Disease.

Wei H, Withrow J, Rakshit J, Ul Amin F, Nahm J, Mowry F Aging Dis. 2024; 15(6):2752-2769.

PMID: 38502590 PMC: 11567244. DOI: 10.14336/AD.2024.0205-1.


Optogenetics in Alzheimer's Disease: Focus on Astrocytes.

Mitroshina E, Kalinina E, Vedunova M Antioxidants (Basel). 2023; 12(10).

PMID: 37891935 PMC: 10604138. DOI: 10.3390/antiox12101856.


Morphological connectivity differences in Alzheimer's disease correlate with gene transcription and cell-type.

Yu H, Ding Y, Wei Y, Dyrba M, Wang D, Kang X Hum Brain Mapp. 2023; 44(18):6364-6374.

PMID: 37846762 PMC: 10681645. DOI: 10.1002/hbm.26512.


Inflammatory Processes in Alzheimer's Disease-Pathomechanism, Diagnosis and Treatment: A Review.

Twarowski B, Herbet M Int J Mol Sci. 2023; 24(7).

PMID: 37047492 PMC: 10095343. DOI: 10.3390/ijms24076518.


Astrocytes as a Therapeutic Target in Alzheimer's Disease-Comprehensive Review and Recent Developments.

Rodriguez-Giraldo M, Gonzalez-Reyes R, Ramirez-Guerrero S, Bonilla-Trilleras C, Guardo-Maya S, Nava-Mesa M Int J Mol Sci. 2022; 23(21).

PMID: 36362415 PMC: 9654484. DOI: 10.3390/ijms232113630.


References
1.
Lui H, Zhang J, Makinson S, Cahill M, Kelley K, Huang H . Progranulin Deficiency Promotes Circuit-Specific Synaptic Pruning by Microglia via Complement Activation. Cell. 2016; 165(4):921-35. PMC: 4860138. DOI: 10.1016/j.cell.2016.04.001. View

2.
Cipriano M, Esposito G, Negro L, Capoccia E, Sarnelli G, Scuderi C . Palmitoylethanolamide Regulates Production of Pro-Angiogenic Mediators in a Model of β Amyloid-Induced Astrogliosis In Vitro. CNS Neurol Disord Drug Targets. 2015; 14(7):828-37. DOI: 10.2174/1871527314666150317224155. View

3.
Verkhratsky A, Nedergaard M, Hertz L . Why are astrocytes important?. Neurochem Res. 2014; 40(2):389-401. DOI: 10.1007/s11064-014-1403-2. View

4.
Griffith C, Eid T, Rose G, Patrylo P . Evidence for altered insulin receptor signaling in Alzheimer's disease. Neuropharmacology. 2018; 136(Pt B):202-215. DOI: 10.1016/j.neuropharm.2018.01.008. View

5.
Reichenbach N, Delekate A, Breithausen B, Keppler K, Poll S, Schulte T . P2Y1 receptor blockade normalizes network dysfunction and cognition in an Alzheimer's disease model. J Exp Med. 2018; 215(6):1649-1663. PMC: 5987918. DOI: 10.1084/jem.20171487. View